AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00758069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Sitagliptin
Description: 50 mg twice daily (BID), taken orally for 4 weeks
Study NCT00179062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine versus risperidone
Description: Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
Study NCT01432457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained-release 50 mg/day
Description: 50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
Study NCT01432457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained-release 100 mg/day
Description: 100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
Study NCT01432457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
Study NCT03123484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-elemene
Description: β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
Study NCT03123484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
Description: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
Study NCT03123484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
Description: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
Study NCT03842501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Release Supplement
Description: Calorie reduced diet plus Release supplement
Study NCT03842501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calorie reduced diet plus Placebo
Study NCT00800930 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Butyrate
Description: Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
Study NCT00800930 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
Study NCT03292536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: \*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks
Study NCT04173624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endosonography
Description: Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
Study NCT04287985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose-VIS649
Description: Dose Level = Low
Study NCT01402024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg
Study NCT04173624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
Study NCT01402024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule).
Study NCT00561340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pediasure
Description: 50% will be randomized to pediasure with nutritional counseling
Study NCT00561340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: 50% randomized to nutritional counseling only
Study NCT00561340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: 50% randomized to nutritional counseling only
Study NCT03441555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet, oral
Study NCT03441555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Description: Intravenous
Study NCT04415190 — intervention group
Intervention type: OTHER
Intervention: early palliative care
Description: early palliative care
Study NCT01041066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol
Description: 0.4 mg/kg labetalol intravenously 4 min before intubation
Study NCT01041066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicardipine
Description: 20 ㎍/kg nicardipine intravenously 4 min before intubation
Study NCT04081766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SUGAR Handshake
Description: An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~1. Signs and symptoms of hypoglycemia.~2. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~3. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~4. Acknowledgement by the patient~5. Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit.
Study NCT04100291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Faecal microbiota transplantation
Description: FMT by daily enema with donor faeces
Study NCT04100291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by daily enema with placebo mixture
Study NCT02511275 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal microdialysis
Description: Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
Study NCT02029456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
Study NCT02603406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Study NCT00222248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training and bladder training
Study NCT00222248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and bladder training
Study NCT04591145 — intervention group
Intervention type: OTHER
Intervention: Observational group
Description: Patient receive the standard bowel preparation strategy and routine colonoscopy
Study NCT02293941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122 5mg
Description: Participants were randomized to receive JKB-122 5mg for 12 weeks
Study NCT02293941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122 15mg
Description: Participants were randomized to receive JKB-122 15mg for 12 weeks
Study NCT02293941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122 35mg
Description: Participants were randomized to receive JKB-122 35mg for 12 weeks
Study NCT02293941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to receive comparable placebo for 12 weeks
Study NCT05070000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiologic examination
Description: Patients underwent US, CT or CT after US
Study NCT00088621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 80mg tablet
Study NCT04469010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Bis-Glycinate Chelate and Vitamin C
Description: 28 mg iron 240 mg vitamin C
Study NCT04469010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Bis-Glycinate Chelate
Description: 28 mg iron
Study NCT04469010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT02564146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and gemcitabine
Description: Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Study NCT02564146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel and gemcitabine
Description: Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Study NCT03540706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Care with C-reactive protein assay in micro method
Description: Care with C-reactive protein assay in micro method
Study NCT04574180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Crown
Description: Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
Study NCT02564146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine mono and nab-paclitaxel and gemcitabine
Description: Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Study NCT04287985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose-VIS649
Description: Dose Level = Medium
Study NCT04287985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose-VIS649
Description: Dose Level = High
Study NCT01166165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 3 tablets of 1000 IU daily for 20 weeks
Study NCT00695500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline tablets, 2 mg per day for 3 weeks
Study NCT01166165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo tablets daily for 20 weeks
Study NCT01830491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT01830491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT01830491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg
Study NCT01830491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 100mg
Study NCT04849962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group received a traditional muffin with butter as the predominant source of fat.
Study NCT04849962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan
Description: Participants in this group received a muffin in which part of the butter was substituted out for pecans.
Study NCT01342107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 114675A multi-purpose disinfecting solution (MPDS)
Description: Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
Study NCT01342107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft contact lens
Description: Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
Study NCT01342107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lens
Description: Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
Study NCT01342107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blister pack solution
Description: Commercially approved storage solution as found in the contact lens blister pack.
Study NCT02588950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500R
Study NCT01853930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Platform for Administering Eye-movement Control Training
Description: The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
Study NCT02141425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT02141425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT04260867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oil
Description: Those randomized to the treatment group will have containers filled with the essential oil of their choice.
Study NCT04260867 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Essential Oil
Description: Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
Study NCT02385253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational training program
Description: The educational training program (intervention) consists of four sequential phases:~1. Knowledge Acquisition~2. Skills Assessment~3. Deliberate Practice~4. Clinical Proficiency
Study NCT01737489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LACE
Description: commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
Study NCT00695500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, 0 mg per day for 3 weeks
Study NCT00976287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion
Description: Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
Study NCT00976287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conserved Therapy
Description: Conserved Therapy
Study NCT00237666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone 20-60 mg BID, taken orally.
Study NCT03995745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence and financial incentives
Description: Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
Study NCT02236273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional text message reminder
Description: Receipt of conventional text message notifying when due for next dose
Study NCT02236273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced text message reminders
Description: Receipt of enhanced text messages notifying when due for next dose coupled with educational information
Study NCT01643265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Milk Protein
Description: 20 grams of Whey Milk Protein
Study NCT01643265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Albumin Concentrate
Description: 20 grams of Bovine Albumin Concentrate
Study NCT02435459 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No lining
Description: No lining material placed under amalgam dental restorations
Study NCT02435459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide cement
Description: placement of lining material under amalgam dental restorations
Study NCT02435459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RMGI cement
Description: placement of lining material under amalgam dental restorations
Study NCT02435459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin Bonding Agent
Description: placement of lining material under amalgam dental restorations
Study NCT00659386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy
Description: Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
Study NCT03780530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcuticular suturing
Description: Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
Study NCT03780530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical glue
Description: Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
Study NCT03780530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adhesive steri-strip tape
Description: Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).